Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapy

Seeking therapeutic synergy in BRAF mutant colorectal cancer

In a phase I trial, the combination of dabrafenib, trametinib and spartalizumab uncovers the crosstalk between the MAPK pathway and the immune system, which offers a promising new strategy to improve clinical outcomes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: BRAF pathway and targeted agents.

References

  1. Davies, H. et al. Nature 417, 949–954 (2002).

    Article  CAS  PubMed  Google Scholar 

  2. Hyman, D. M. et al. N. Engl. J. Med. 373, 726–736 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Corcoran, R. B. et al. Cancer Discov. 2, 227–235 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Corcoran, R. B. et al. Cancer Discov. 8, 428–443 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Tian, J. Nat. Med. https://doi.org/10.1038/s41591-022-02181-8 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kopetz, S. et al. N. Engl. J. Med. 381, 1632–1643 (2019).

    Article  CAS  PubMed  Google Scholar 

  7. Eng, C. et al. Lancet Oncol. 20, 849–861 (2019).

    Article  CAS  PubMed  Google Scholar 

  8. Guinney, J. et al. Nat. Med. 21, 1350–1356 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Andre, T. et al. J. Clin. Oncol. 38, LBA4 (2020). 18 suppl.

    Article  Google Scholar 

  10. Le, D. T. et al. N. Engl. J. Med. 372, 2509–2520 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Elez, E. et al. Nat. Med. 28, 2162–2170 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Morris, V. K. et al. J. Clin. Oncol. 40, 12 (2022). 4 suppl.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Elena Elez.

Ethics declarations

Competing interests

E.E. has received personal speaker honoraria from Organon and Novartis; and personal advisory board honoraria from Amgen, Bayer, Hoffman-La Roche, Merck Serono, Sanofi, Pierre Fabre, MSD, and Servier. Educational collaboration with Imedex/HMP and PeerView Institute for Medical Education. J.R. has received personal speaker honoraria from Sanofi and AMGEN, and accommodation expenses from Pierre-Fabre, Servier, Amgen and Merck. J.T. reports personal financial interest in form of scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Tessa Therapeutics and TheraMyc. Stocks: Oniria Therapeutics and also educational collaboration with Imedex/HMP, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elez, E., Ros, J. & Tabernero, J. Seeking therapeutic synergy in BRAF mutant colorectal cancer. Nat Med 29, 307–308 (2023). https://doi.org/10.1038/s41591-022-02192-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-02192-5

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer